Search for a trial

A double-blind, randomised, placebo-controlled multicenter study to asses the safety and efficacy of AST-120 in mild to moderately active Crohn's patients with fistulas.

The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8